Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P0C870

UPID:
JMJD7_HUMAN

ALTERNATIVE NAMES:
JmjC domain-containing protein 7; Jumonji domain-containing protein 7; L-lysine (3S)-hydroxylase JMJD7

ALTERNATIVE UPACC:
P0C870; A5D6V5; O95712; Q59GF9; Q8TB10; Q9UKV7

BACKGROUND:
The enzyme Bifunctional peptidase and (3S)-lysyl hydroxylase JMJD7, with alternative names such as Jumonji domain-containing protein 7, is pivotal in epigenetic and translational processes. It selectively cleaves methylated arginine or lysine residues of histones, facilitating transcription elongation, and hydroxylates lysine residues on DRG1 and DRG2, enhancing their RNA binding. Its unique enzymatic activities make it a key player in gene expression and protein translation.

THERAPEUTIC SIGNIFICANCE:
Exploring the multifaceted functions of Bifunctional peptidase and (3S)-lysyl hydroxylase JMJD7 holds promise for unveiling novel therapeutic avenues.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.